Prognostic value of PD-L1 expression in patients with anal cancer: a meta-analysis

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2024-05-03 DOI:10.2217/bmm-2023-0727

Siqi Gong, Jiafeng Song

引用次数: 0

Abstract

Background: The present meta-analysis was performed to evaluate the prognostic and clinicopathological significance of PD-L1 in anal cancer (AC). Methods: Hazard ratios (HRs) and 95% CIs regarding overall survival (OS) and progression-free survival (PFS) were calculated based on PD-L1 levels. Results: According to the combined data, PD-L1 showed no significant relationship with OS (HR = 0.76; 95% CI = 0.35–1.67; p = 0.502) or PFS (HR = 0.88; 95% CI = 0.35–2.33; p = 0.789) in patients with AC. Based on subgroup analysis, PD-L1 overexpression significantly predicted prolonged OS (HR = 0.38; 95% CI = 0.17–0.84; p = 0.017) in tumor node metastasis stages I–III and inferior PFS (HR = 2.73; 95% CI = 1.32–5.65; p = 0.007) in patients with stage I–IV AC. Conclusion: PD-L1 level assessed by immunohistochemistry did not significantly predict survival outcomes in AC cases.

查看原文本刊更多论文

肛门癌患者 PD-L1 表达的预后价值：一项荟萃分析

背景本荟萃分析旨在评估 PD-L1 在肛门癌（AC）中的预后和临床病理学意义。方法：根据 PD-L1 水平计算总生存期（OS）和无进展生存期（PFS）的危险比（HRs）和 95% CIs。结果综合数据显示，PD-L1 与 AC 患者的 OS（HR = 0.76；95% CI = 0.35-1.67；P = 0.502）或 PFS（HR = 0.88；95% CI = 0.35-2.33；P = 0.789）无显著关系。根据亚组分析，PD-L1过表达可显著延长I-III期肿瘤结节转移患者的OS（HR = 0.38; 95% CI = 0.17-0.84; p = 0.017），并降低I-IV期AC患者的PFS（HR = 2.73; 95% CI = 1.32-5.65; p = 0.007）。结论通过免疫组化评估的PD-L1水平并不能显著预测AC病例的生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.